RS81604A - Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor - Google Patents

Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Info

Publication number
RS81604A
RS81604A YU81604A YUP81604A RS81604A RS 81604 A RS81604 A RS 81604A YU 81604 A YU81604 A YU 81604A YU P81604 A YUP81604 A YU P81604A RS 81604 A RS81604 A RS 81604A
Authority
RS
Serbia
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
alkynyl
Prior art date
Application number
YU81604A
Other languages
English (en)
Inventor
Patrick Page
Lebrun Catherine Jorand
Anna Quattropani
Vincent Pomel
Matthias Schwarz
Estelle Hamelin
Russell Thomas
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of RS81604A publication Critical patent/RS81604A/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na derivate tijazolidin karboksamida formule (II) za lečenje i/ili profilaksu prevremenih trudova, prevremenog porođaja, dimenoreje i za zaustavljanje trudova pred carski rez. G se odabira iz grupe čiji je sadržaj C1-C6-alkil aril, C1-C6-alkil heteroaril, C1-C6-alkilcikloalkil, C1-C6-alkil heteroaril, aril, heteroaril, C3-C8-cikloalkil ili -heterociklo-alkil, pomenuti cikloalkil ili aril ili heteroaril grupe mogu biti spojene sa cikloalkil ili aril ili heteroaril grupe. R1 se odabira iz grupe čiji je sadržaj aril, heteroaril, C3-C8-cikloalkil ili -heterociklo-alkil, pomenuti (hetero)cikloalkil ili aril ili heteroarill grupe mogu biti spojene sa (hetero)cikloalkil ili aril ili heteroaril grupe. R2 se odabira iz grupe čiji je sadržaj H, karboksi, acil, alkoksikarbonil, amino-karbonil, C1-C5-alkil karboksi, C1-C5-alkil acil, C1-C5-alkil alkoksikarbonil, C1-C5-alkil aminokarbonil, C1-C5-alkil aciloksi, C1-C5-alkil acilamino, C1-C5-alkil ureido, C1-C5-alkil amino, C1-C5-alkil alkoksi, C1-C5-alkil sulfanil, C1-C5-alkil sulfinil, C1-C5-alkil sulfonil, C1-C5-alkil sulfonilamino, C1-C5-alkil sulfoniloksi, C1-C6-alkil, C2-C6-alkenil, C2-C6-alkinil, aril, heteroaril, C3-C8-cikloalkil, heterocikloalkil, C1-C6-alkil aril, C2-C6-alkil heteroaril, C1-C6-alkil cikloalkil, C1-C6-alkil heterocikloalkil, C2-C6-alkenil aril, C2-C6-alkenil heteroaril, C2-C6-alkinil aril, ili C2-C6-alkinil heteroaril.
YU81604A 2002-03-28 2003-03-27 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor RS81604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100314 2002-03-28
PCT/EP2003/050083 WO2003082278A1 (en) 2002-03-28 2003-03-27 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Publications (1)

Publication Number Publication Date
RS81604A true RS81604A (en) 2006-12-15

Family

ID=28459561

Family Applications (1)

Application Number Title Priority Date Filing Date
YU81604A RS81604A (en) 2002-03-28 2003-03-27 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Country Status (22)

Country Link
US (2) US20050215605A1 (sr)
EP (1) EP1487442B1 (sr)
JP (1) JP4602672B2 (sr)
KR (1) KR20040095311A (sr)
CN (1) CN100484524C (sr)
AT (1) ATE489951T1 (sr)
AU (2) AU2003240757B2 (sr)
BR (1) BR0308748A (sr)
CA (1) CA2477265A1 (sr)
DE (1) DE60335175D1 (sr)
EA (1) EA007328B1 (sr)
ES (1) ES2360882T3 (sr)
HK (1) HK1075215A1 (sr)
HR (1) HRP20040759A2 (sr)
IL (1) IL164212A0 (sr)
MX (1) MXPA04009374A (sr)
NO (1) NO20044262L (sr)
PL (1) PL372919A1 (sr)
RS (1) RS81604A (sr)
UA (1) UA78021C2 (sr)
WO (1) WO2003082278A1 (sr)
ZA (1) ZA200406763B (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007328B1 (ru) * 2002-03-28 2006-08-25 Апплайд Резеч Системз Арс Холдинг Н. В. Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
MXPA05007513A (es) 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
MY150129A (en) 2004-04-09 2013-11-29 Archer Daniels Midland Co Method of preparing fatty acid alkyl esters from waste or recycled fatty acid stock
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
CA3045407C (en) 2009-07-29 2024-03-12 Elise A. Olsen Compositions and methods for inhibiting hair growth
MX2013015274A (es) 2011-06-24 2014-03-31 Amgen Inc Anatagonista trpm8 y su uso en tratamientos.
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3061754A4 (en) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2017205670B2 (en) * 2016-01-04 2021-05-20 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US9447055B1 (en) 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
CN109790133A (zh) * 2016-01-04 2019-05-21 奥布赛瓦股份公司 羟丙基噻唑烷羧酰胺衍生物的α-氨基酯及其盐形式、晶体多形体
EA039545B1 (ru) * 2016-10-13 2022-02-09 Обсева С.А. Способы предотвращения преждевременных родов с помощью комбинации ингибитора pgf2 и токолитического агента
US11289654B2 (en) 2016-12-22 2022-03-29 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymers containing furanyl crosslinkable groups and uses thereof
US11534428B1 (en) 2018-05-16 2022-12-27 Xoma (Us) Llc Compositions and methods for delaying the incidence of labor
US20240024294A1 (en) 2020-11-16 2024-01-25 Xoma (Us) Llc Compositions and methods for the treatment or prevention of preterm labor
US20240024295A1 (en) * 2020-12-11 2024-01-25 Elise A. Olsen Compositions and methods for inhibiting hair growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016270A (en) * 1975-10-31 1977-04-05 Alza Corporation Method for treating dysmenorrhea with a uterine therapeutic system
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
JPS6450818A (en) * 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US6271201B1 (en) * 1993-07-15 2001-08-07 Board Of Regents, The University Of Texas System Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
AU727820B2 (en) * 1996-08-28 2000-12-21 Procter & Gamble Company, The 1,3-diheterocyclic metalloprotease inhibitors
EP1001975A1 (en) * 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
EA007328B1 (ru) * 2002-03-28 2006-08-25 Апплайд Резеч Системз Арс Холдинг Н. В. Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f

Also Published As

Publication number Publication date
US20080255094A1 (en) 2008-10-16
US20050215605A1 (en) 2005-09-29
US8415480B2 (en) 2013-04-09
CN100484524C (zh) 2009-05-06
EA200401270A1 (ru) 2005-02-24
HRP20040759A2 (en) 2004-12-31
IL164212A0 (en) 2005-12-18
HK1075215A1 (en) 2005-12-09
ZA200406763B (en) 2005-09-30
DE60335175D1 (de) 2011-01-13
NO20044262L (no) 2004-10-07
BR0308748A (pt) 2005-01-11
EP1487442B1 (en) 2010-12-01
EP1487442A1 (en) 2004-12-22
KR20040095311A (ko) 2004-11-12
CN1655780A (zh) 2005-08-17
PL372919A1 (en) 2005-08-08
AU2003240757B2 (en) 2008-07-03
UA78021C2 (en) 2007-02-15
MXPA04009374A (es) 2005-01-25
ATE489951T1 (de) 2010-12-15
ES2360882T3 (es) 2011-06-10
AU2003240757A1 (en) 2003-10-13
US20090215749A9 (en) 2009-08-27
EA007328B1 (ru) 2006-08-25
AU2008207407A1 (en) 2008-09-11
WO2003082278A1 (en) 2003-10-09
JP2005531524A (ja) 2005-10-20
CA2477265A1 (en) 2003-10-09
JP4602672B2 (ja) 2010-12-22

Similar Documents

Publication Publication Date Title
RS81604A (en) Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
MX2022007317A (es) Inhibidores novedosos.
PE20120589A1 (es) DERIVADOS DE N-FENIL-1H-BENZIMIDAZOL-2-AMINA COMO INHIBIDORES DE PROSTAGLANDINA MICROSOMICA E2 SINTASA-1 (mPGES-1)
AR050941A1 (es) SERINAMIDAS SUSTITUIDAS POR BENZOILO, PROCESOS PARA SU PREPARACION, INTERMEDIARIOS PARA SU SINTESIS, USO DE LAS MISMAS EN LA FABRICACIoN DE PRODUCTOS FITOSANITARIOS Y PROCEDIMEITNSO PARA CONTROLAR EL CRECIMIENTO DE PLANTAS INDESEADAS
NO20092038L (no) Tiofenanaloger for behandling eller prevensjon av flavivirusinfeksjoner
PH12015502192A1 (en) Novel compounds
RS52099B (sr) Supstituisani benzimidazoli kao inhibitori kinaze
AR063680A1 (es) Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
ATE500215T1 (de) Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
ES2572155T3 (es) Compuestos insecticidas
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
AR052886A1 (es) Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
AR047367A1 (es) Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral
AR062464A1 (es) Amidas picolinicas de acido tiofen-sulfonico
NZ594641A (en) Pyrazole derivatives used as ccr4 receptor antagonists
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
MX2009004526A (es) Nuevos derivados de benzamida como antagonistas de la bradiqunina.
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
EA201100368A1 (ru) Амидные соединения, полезные в терапии
RU2008127445A (ru) Бициклические гетероциклические соединения в качестве противовоспалительных или антиаллергических агентов
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1